Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xuezhikang vs Atorvastatin in Dyslipidemia with Prediabetes
NCT06750783Phase 4Recruiting
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Dec 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Xuezhikang in dyslipidemia, prediabetes, sponsored by Beijing Tsinghua Changgung Hospital. Started Dec 2024; status: recruiting.
02
Drugs
Xuezhikang
03
Conditions
dyslipidemiaprediabetes
Beyond the preview
Go deeper on NCT06750783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06750783.